Hodgkin lymphoma in the Swiss HIV Cohort Study

Hodgkin lymphoma in the Swiss HIV Cohort Study
复制标题

DOI：
10.1182/blood-2009-02-204172
复制
发表时间：
2009-06-04
期刊：
BLOOD
影响因子：
20.3
通讯作者：
Franceschi, Silvia
Franceschi, Silvia
中科院分区：
医学1区
文献类型：
--
作者：
Clifford, Gary M.;Rickenbach, Martin;Franceschi, Silvia

文献摘要

被引文献

相似文献

霍奇金淋巴瘤（HL）的风险在HIV（PHIV）感染者中升高，并且在联合抗逆转录病毒治疗（cART）时代已经增加。在瑞士HIV队列研究（SHCS）中随访超过20年的14 606例PHIV中，使用2种不同方法（即队列和巢式病例对照研究）研究HL的决定因素，分别估计风险比（HR）和匹配比值比。在84611人-年的SHCS随访期间，发生了47例HL事件。男男性行为者的HL风险显著较高（HR vs静脉注射吸毒者= 2.44，95%置信区间[CI]，1.13 - 5.24），但不随日历周期变化（2002 - 2007年与1995年或更早的HR = 0.65，95% CI，0.29 - 1.44）或cART使用（HR与非使用者= 1.02，95% CI，0.53 - 1.94）。HL风险倾向于随着CD4（+）细胞计数的下降而增加，但这些差异并不显著。然而，SHCS入组时或HL诊断前1 - 2年较低的CD4（+）/CD8（+）比值与HL风险增加显著相关。总之，近年来或在瑞士使用cART的PHIV中，HL风险似乎并未增加，并且没有证据表明在免疫力提高的情况下HL风险应增加。（血。2009; 113：5737 - 5742）
Hodgkin lymphoma (HL) risk is elevated among persons infected with HIV (PHIV) and has been suggested to have increased in the era of combined antiretroviral therapy (cART). Among 14 606 PHIV followed more than 20 years in the Swiss HIV Cohort Study (SHCS), determinants of HL were investigated using 2 different approaches, namely, a cohort and nested case-control study, estimating hazard ratios (HRs) and matched odds ratios, respectively. Forty-seven incident HL cases occurred during 84 611 person-years of SHCS follow-up. HL risk was significantly higher among men having sex with men (HR vs intravenous drug users = 2.44, 95% confidence interval [CI], 1.13-5.24) but did not vary by calendar period ( HR for 2002-2007 vs 1995 or earlier = 0.65, 95% CI, 0.29-1.44) or cART use ( HR vs nonusers = 1.02, 95% CI, 0.53-1.94). HL risk tended to increase with declining CD4(+) cell counts, but these differences were not significant. A lower CD4(+)/CD8(+) ratio at SHCS enrollment or 1 to 2 years before HL diagnosis, however, was significantly associated with increased HL risk. In conclusion, HL risk does not appear to be increasing in recent years or among PHIV using cART in Switzerland, and there was no evidence that HL risk should be increased in the setting of improved immunity. (Blood. 2009; 113: 5737-5742)